Carotegrast methyl - EA Pharma
Alternative Names: AJM 300; CAROGRALatest Information Update: 04 Aug 2023
At a glance
- Originator Ajinomoto
- Developer EA Pharma
- Class Anti-inflammatories; Chlorobenzenes; Dimethylamines; Esters; Quinazolines; Small molecules
- Mechanism of Action Alpha4beta7 integrin antagonists; Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Discontinued Crohn's disease
Most Recent Events
- 28 Mar 2023 EA Pharma and Kissei Pharmaceutical completes a phase III trial for Ulcerative colitis (In adolescents, In adults, In the elderly) in Japan (NCT03531892)
- 30 May 2022 Launched for Ulcerative colitis in Japan (PO)
- 28 Mar 2022 First global approval - Registered for Ulcerative colitis in Japan (PO)